SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Verona Pharma plc (VRNA) , forward earnings yield 1.11%. PEG 1.33.
Criteria proven by this page:
- VALUE (50/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 90.0
- PEG Ratio 1.33 — between 1.0–2.0 indicates moderate valuation relative to growth.
- Analyst consensus target $107.00 (+0.1% upside) — modest upside expected.
Overall SharesGrow Score: 33/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
50/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — VRNA
Valuation Multiples
P/E (TTM)0.0
Forward P/E90.0
PEG Ratio1.33
Forward PEG1.33
P/B Ratio0.00
P/S Ratio206.19
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-2.16
Forward EPS (Est.)$1.19
Book Value / Share$0.00
Revenue / Share$0.52
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield1.11%
Dividend Yield0.00%
Analyst Target$107.00 (+0.1%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-4.32 |
$0.00 |
$-10.99M |
- |
| 2016 |
$-1.44 |
$0.00 |
$-6.19M |
- |
| 2017 |
$-2.56 |
$1.84M |
$-27.7M |
-1504.6% |
| 2018 |
$-1.92 |
$2.78K |
$-25.25M |
-907384.5% |
| 2019 |
$-3.20 |
$2.35K |
$-41.88M |
-1781367.5% |
| 2020 |
$-2.00 |
$0.00 |
$-65.15M |
- |
| 2021 |
$-0.96 |
$40M |
$-55.57M |
-138.9% |
| 2022 |
$-1.04 |
$458K |
$-68.7M |
-15000.2% |
| 2023 |
$-0.69 |
$0.00 |
$-54.37M |
- |
| 2024 |
$-2.16 |
$42.28M |
$-173.42M |
-410.2% |
